Other studies have also noted that HER2-low tumors in HR-positive cases are more often diagnosed in younger women, while in HR-negative subtypes, especially triple-negative breast cancer, they are more frequently seen in older patients [12-15]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.